Julien Hanson

Dr. Julien Hanson

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Cell Metabolism
Verified
Journal Article
Closed access
KAKashan Ahmed
Kashan Ahmed
Sorin TunaruSorin Tunaru
Sorin Tunaru
CTCong Tang
Cong Tang
MMMichaela Müller
Michaela Müller
AGAndreas Gille
Andreas Gille
SOStefan Offermanns
Stefan Offermanns

16 September 2021 in British Journal of Pharmacology
Verified
Journal Article
Open access
SASteve Alexander
Steve Alexander
ACArthur Christopoulos
Arthur Christopoulos
ADAnthony P Davenport
Anthony P Davenport
EKEamonn Kelly
Eamonn Kelly
AMAlistair Mathie
Alistair Mathie
RYRichard D. Ye
Richard D. Ye
The Concise Guide to PHARMACOLOGY 2021/22 is the fifth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of nearly 1900 human drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes over 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found athttp://onlinelibrary.wiley.com/doi/bph.15538. G protein‐coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2021, and supersedes data presented in the 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

1 October 2023 in British Journal of Pharmacology
Verified
Journal Article
Open access
SASteve Alexander
Steve Alexander
ACArthur Christopoulos
Arthur Christopoulos
ADAnthony P. Davenport
Anthony P. Davenport
EKEamonn Kelly
Eamonn Kelly
AMAlistair A. Mathie
Alistair A. Mathie
RYRichard D. Ye
Richard D. Ye
The Concise Guide to PHARMACOLOGY 2023/24 is the sixth in this series of biennial publications. The Concise Guide provides concise overviews, mostly in tabular format, of the key properties of approximately 1800 drug targets, and about 6000 interactions with about 3900 ligands. There is an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (https://www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. Although the Concise Guide constitutes almost 500 pages, the material presented is substantially reduced compared to information and links presented on the website. It provides a permanent, citable, point‐in‐time record that will survive database updates. The full contents of this section can be found at http://onlinelibrary.wiley.com/doi/bph.16177. G protein‐coupled receptors are one of the six major pharmacological targets into which the Guide is divided, with the others being: ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison of related targets from material contemporary to mid‐2023, and supersedes data presented in the 2021/22, 2019/20, 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is produced in close conjunction with the Nomenclature and Standards Committee of the International Union of Basic and Clinical Pharmacology (NC‐IUPHAR), therefore, providing official IUPHAR classification and nomenclature for human drug targets, where appropriate.

2 August 2010 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
JHJulien Hanson
Julien Hanson
AGAndreas Gille
Andreas Gille
SZSabrina Zwykiel
Sabrina Zwykiel
MLMartina Lukasova
Martina Lukasova
Björn Erik CLAUSENBjörn Erik CLAUSEN
Björn Erik CLAUSEN
SOStefan Offermanns
Stefan Offermanns
The antidyslipidemic drug nicotinic acid and the antipsoriatic drug monomethyl fumarate induce cutaneous flushing through activation of G protein–coupled receptor 109A (GPR109A). Flushing is a troublesome side effect of nicotinic acid, but may be a direct reflection of the wanted effects of monomethyl fumarate. Here we analyzed the mechanisms underlying GPR109A-mediated flushing and show that both Langerhans cells and keratinocytes express GPR109A in mice. Using cell ablation approaches and transgenic cell type–specific GPR109A expression in Gpr109a–/– mice, we have provided evidence that the early phase of flushing depends on GPR109A expressed on Langerhans cells, whereas the late phase is mediated by GPR109A expressed on keratinocytes. Interestingly, the first phase of flushing was blocked by a selective cyclooxygenase-1 (COX-1) inhibitor, and the late phase was sensitive to a selective COX-2 inhibitor. Both monomethyl fumarate and nicotinic acid induced PGE2 formation in isolated keratinocytes through activation of GPR109A and COX-2. Thus, the early and late phases of the GPR109A-mediated cutaneous flushing reaction involve different epidermal cell types and prostanoid-forming enzymes. These data will help to guide new efficient approaches to mitigate nicotinic acid–induced flushing and may help to exploit the potential antipsoriatic effects of GPR109A agonists in the skin.

1 March 2016 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
JGJulie Gilissen
Julie Gilissen
FJFrançois Jouret
François Jouret
BPBernard Pirotte
Bernard Pirotte
JHJulien Hanson
Julien Hanson

1 July 2018 in Biochemical Pharmacology
Verified
Journal Article
Closed access
CLCéline Laschet
Céline Laschet
NDNadine Dupuis
Nadine Dupuis
JHJulien Hanson
Julien Hanson